• Traitements

  • Traitements systémiques : découverte et développement

  • Leucémie

Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL

Menée in vitro et in vivo, cette étude évalue l'activité antitumorale de l'alisertib, un inhibiteur de la kinase Aurora A, dans la leucémie aiguë à mégacaryocytes

The mechanism by which cells decide to skip mitosis to become polyploid is largely undefined. Here we used a high-content image-based screen to identify small-molecule probes that induce polyploidization of megakaryocytic leukemia cells and serve as perturbagens to help understand this process. Our study implicates five networks of kinases that regulate the switch to polyploidy. Moreover, we find that dimethylfasudil (diMF, H-1152P) selectively increased polyploidization, mature cell-surface marker expression, and apoptosis of malignant megakaryocytes. An integrated target identification approach employing proteomic and shRNA screening revealed that a major target of diMF is Aurora kinase A (AURKA). We further find that MLN8237 (Alisertib), a selective inhibitor of AURKA, induced polyploidization and expression of mature megakaryocyte markers in acute megakaryocytic leukemia (AMKL) blasts and displayed potent anti-AMKL activity in vivo. Our findings provide a rationale to support clinical trials of MLN8237 and other inducers of polyploidization and differentiation in AMKL. º Screen identifies > 200 compounds regulating megakaryocyte polyploidization º Integrated target identification approach suggests regulatory kinase networks º Aurora kinase A activity mediates megakaryocyte polyploidization and differentiation º Induction of polyploidization provides a therapeutic strategy for AMKL Megakaryocytes undergo a modified form of the cell cycle termed endomitosis, in which cells skip the late stages of mitosis to become polyploid. Using a chemical screening approach, Wen et al. now provide insight into the protein kinase networks that regulate endomitosis and reveal a differentiation therapy strategy for the treatment of acute megakaryocytic leukemia.

Cell 2012

Voir le bulletin